US2008161286A1PendingUtilityA1

Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

Assignee: SERVIER LABPriority: Feb 28, 2005Filed: Feb 27, 2008Published: Jul 3, 2008
Est. expiryFeb 28, 2025(expired)· nominal 20-yr term from priority
A61P 9/04A61P 9/00A61P 9/06A61P 9/10B01J 21/04B01J 23/892B01J 23/622B01J 23/8926A61K 31/55C10G 45/34B01J 37/0213C07D 223/16B01J 23/626B01J 23/50B01J 37/0211B01J 23/62C07B 2200/13B01J 35/397
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A βd-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.

Claims

exact text as granted — not AI-modified
1 . A βd-Crystalline form of ivabradine hydrochloride of formula (I): 
       
         
           
           
               
               
           
         
       
     
     
         2 . The βd-Crystalline form of ivabradine hydrochloride of  claim 1  having a powder X-ray diffraction diagram exhibiting peaks at 9.2 and 13.6 deg 2 theta. 
     
     
         3 . The βd-Crystalline form of ivabradine hydrochloride of  claim 1  having a powder X-ray diffraction diagram exhibiting peaks at 9.2, 12.5, 13.6, 17.3, 22.3 and 25.0 deg 2 theta. 
     
     
         4 . A pharmaceutical composition comprising as active ingredient the βd-crystalline form of ivabradine hydrochloride of  claim 1 , in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. 
     
     
         5 . A method for treating or preventing a condition requiring a bradycardic, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of the βd-crystalline form of ivabradine hydrochloride of  claim 1 . 
     
     
         6 . A method for treating or preventing clinical situations of myocardial ischaemia and/or a condition involving rhythm disturbances, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of the βd-crystalline form of ivabradine hydrochloride of  claim 1 . 
     
     
         7 . The method of  claim 6 , wherein the clinical situation of myocardial ischaemia is selected from angina pectoris and myocardial infarct and associated rhythm disturbances. 
     
     
         8 . The method of  claim 6 , wherein the condition involving rhythm disturbances is selected from supra ventricular rhythm disturbances and heart failure.

Join the waitlist — get patent alerts

Track US2008161286A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.